Patents by Inventor Alexander E. Valdes

Alexander E. Valdes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZIMIDAZOLES AS MODULATORS OF IL-17
    Publication number: 20250122181
    Abstract: The present application discloses compounds having the following formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and X are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: April 17, 2025
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven D. Goldberg, Douglas C. Behenna, Steven A. Loskot, Stefan J. McCarver, Timothy B. Rhorer, Kristin G. Song, Alexander E. Valdes, Craig R. Woods, Xiahua Xue, Brock T. Shireman, Virginia M. Tanis, Deane Gordan
  • IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
    Publication number: 20250109137
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: October 4, 2024
    Publication date: April 3, 2025
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Kristen Song, Alexander E. Valdes, Dongpei Wu, Xiaohua Xue
  • Imidazopyridazine IL-17 inhibitor compounds
    Patent number: 12215111
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: February 4, 2025
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Brock T. Shireman, Alexander E. Valdes, Jennifer D. Venable, Dongpei Wu
  • Imidazopyridazine IL-17 inhibitor compounds
    Patent number: 12173007
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: December 24, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven D. Goldberg, Dougas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Kristen Song, Alexander E. Valdes, Xiaohua Xue
  • IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
    Publication number: 20230143050
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: May 11, 2023
    Inventors: Steven D. Goldberg, Dougas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Kristen Song, Alexander E. Valdes, Dongpei Wu, Xiaohua Xue
  • IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
    Publication number: 20230147458
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: May 11, 2023
    Inventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Brock T. Shireman, Alexander E. Valdes, Jennifer D. Venable, Dongpei Wu, Xiaohua Xue